견적문의

INGELHEIM, GERMANY--( / )--Boehringer Ingelheim today announced that the European Commission has approved nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults.[2] The approval comes after the Committee for Medicinal Products for Human Use had adopted a positive opinion for nintedanib in treatment of SSc-ILD on 27 February 2020.

Systemic sclerosis (SSc), also known as scleroderma, is a disfiguring, disabling and potentially fatal rare autoimmune disease.[3,4,5] It causes scarring (fibrosis) of various organs, including the lungs, heart, digestive tract and kidneys and can lead to life-threatening complications. When the lungs are affected, it can cause interstitial lung disease (ILD), known as SSc-ILD.[1,6] ILD is a leading cause of mortality, accounting for almost 35% of SSc-related deaths.[7]

“This is a real breakthrough in the treatment of people living with SSc-ILD,” said Peter Fang, Senior Vice President and Head of Therapeutic Area Inflammation at Boehringer Ingelheim. ”Once fibrosis of the lungs occurs it cannot be reversed. Nintedanib, being the first and only approved treatment for SSc-ILD, is serving a high unmet need making a real positive difference to those living with this life-changing condition. The approval is a further milestone in Boehringer Ingelheim’s ongoing dedication for people living with pulmonary fibrosis.”

“The European Commission’s decision is very welcome news for the European scleroderma community,” commented Sue Farrington, President of the Federation of European Scleroderma Associations (FESCA). “When scleroderma affects the lungs, there can be severe consequences. The availability of a therapy option brings great hope to those living with scleroderma and their loved ones.”

The European Commission’s approval is based on the results of the SENSCIS® trial, a Phase III, double-blind, placebo-controlled trial conducted to investigate the efficacy and safety of nintedanib in patients with SSc-ILD.[1] The primary endpoint was the annual rate of decline in forced vital capacity (FVC) assessed over a 52-week period. Results showed nintedanib slowed the loss of pulmonary function by 44% (41mL/year) relative to placebo, as measured in FVC over 52 weeks.[1] Furthermore, results showed that nintedanib had a safety and tolerability profile similar to that observed in patients with idiopathic pulmonary fibrosis (IPF).[1]

Regulatory approvals for the treatment of patients living with SSc-ILD have also been granted in several countries including Canada, Japan and Brazil. Nintedanib is approved in over 75 countries for the treatment of IPF, and it is the first approved treatment for SSc-ILD.[8]

Please click on the link for ‘Notes to Editors’ and ‘References’:

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

TORONTO--( / )--Slice Labs Inc., a leading 부산아이파크 민효린속옷화보 on-demand 이비자넷 TORONTO--(cloud platform provider, announced today the opening of the Slice Launch Studio in downtown Toronto, which is designed to be an innovation hub 부산아이파크 프로포폴맞는이유 for Slice and its partners to ideate, experiment, test 연지동홀덤펍 드래곤3 부작용 and deploy new on-demand insurance products on the Slice Insurance Cloud Services (ICS) platform.

Insurers and technology companies from around the world can 부산아이파크 levitra 효능 come to the Launch Studio to collaborate on Hackathons, a key step in Slice’s 연지동홀덤펍 approach to getting product to market quickly. Slice will also host events year-round, bringing together thought leaders from across the globe 연지동홀덤펍 속옷모델알바 to discuss and address emerging and 부산아이파크 increasing risks. Slice is currently working with insurers in the U.S., Canada, 부산아이파크 일더하기일은귀요미시발년 UK and SE Asia to launch new on-demand insurance products, using a minimum viable product methodology which allows for launch in under three months.

The Co-operators Group is the pilot partner for the Launch Studio, who recently launched 부산아이파크 자주먹으면 duuo, both its new digital insurance business unit and of its on-demand homeshare insurance product, via Slice ICS. The carrier will host 연지동홀덤펍 해피그라정 a hackathon on 조pd파라다이스 Theday with the goal to build the vision for 부산아이파크 its next on-demand insurance product. 연지동홀덤펍 현아중학교

“We couldn’t be more excited 부산아이파크 to be a 부산아이파크 발탁스정 part of today’s launch. Our young partnership with Slice is already spurring all sorts of innovative products and ideas at both duuo and The Co-operators. Slice Launch Studio will take that one step further by bringing together the brightest insurance and technology minds from around the globe, truly putting Canada on the map 연지동홀덤펍 as 부산아이파크 백보람합성심경 a new hub for digital insurance innovation,” said Peter Primdahl, Head of Operations at 연지동홀덤펍 박해진김아중 duuo.

“We have seen amazing results for ICS users by creating a fun 부산아이파크 이승기김아중 and engaging environment to reinvent one of the world’s most established industries,” said Tim Attia, CEO of Slice Labs. 부산아이파크 음란물차단 “On-demand insurance is not just limited to insurers. 연지동홀덤펍 카마그라젤 Opening the Launch Studio to technology companies that are considering integrating on-demand insurance into existing digital 부산아이파크 온라인게임추천사이트 products solidifies Slice’s transition from solely being an on-demand homeshare insurer to an award-winning cloud computing vendor.”

The Slice Launch Studio is located on the 42nd floor of the Scotia Plaza (40 King St. West, Toronto), and is open from 9-5 p.m. ET Monday 부산아이파크 좋은공부사이트 - Friday by appointment to protect the ICS user intellectual capital. Participants 연지동홀덤펍 can make appointments 연지동홀덤펍 주블리아 at

About 부산아이파크 꿀맛닷컴 연지동홀덤펍 꿀맛닷컴 Slice: 부산아이파크 무료공부사이트 연지동홀덤펍 무료공부사이트

Slice Labs is a leading on-demand insurance cloud platform provider that empowers insurers to deliver new value 부산아이파크 영문번역사이트 to customers through direct insurance or insurance agent models without investing in infrastructure to provide 부산아이파크 customized 연지동홀덤펍 엘크라넬 on-demand, pay-as-you-go insurance products. The Slice Insurance Cloud Services platform (ICS) is powered by machine learning and advanced big data technologies along with Ph.D. behavioral science expertise. ICS is the foundation for new digital insurance products being released globally by top insurers and is also the base 연지동홀덤펍 발기부전제종류 for Slice’s own digital insurance products serving the new economy. To stay up to date with Slice, 부산아이파크 인덕원코넬 visit and follow 연지동홀덤펍 센돔효과 @SliceLabs on Twitter.

View source version on businesswire.com:Korea 부산아이파크 일본취업사이트 Newswire distributes your news across 연지동홀덤펍 병원취업사이트 every media channels through 부산아이파크 취업사이트추천 연지동홀덤펍 취업사이트추천 월미동성인게임장 View부산아이파크 취업 industry’s largest press release distribution network